Sage Therapeutics, Inc. Form 4

June 22, 2015

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Arch Venture Fund VII LP

(First)

(Middle)

8725 WEST HIGGINS ROAD. **SUITE 290.** 

(Street)

2. Issuer Name and Ticker or Trading Symbol

Sage Therapeutics, Inc. [SAGE]

4. If Amendment, Date Original

3. Date of Earliest Transaction (Month/Day/Year)

Filed(Month/Day/Year)

06/18/2015

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner Other (specify Officer (give title

below)

7. Nature of

Indirect

Beneficial

Ownership

(Instr. 4)

(9-02)

Applicable Line)

Form filed by One Reporting Person X Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

CHICAGO, IL 60631

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially (Month/Day/Year) (Instr. 8) Owned Following Reported (A) Transaction(s) or (Instr. 3 and 4) (D) Price

 $J^{(1)}$ 

Common Stock

06/18/2015

Code V Amount

1,062,345

(1)

2,124,699

 $D^{(2)(3)}$ 

Ownership

Direct (D)

or Indirect

(Instr. 4)

Form:

(I)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: Sage Therapeutics, Inc. - Form 4

	1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transactio	5. orNumber	6. Date Exerc Expiration D		7. Title		8. Price of Derivative	9. Nu Deriv
	Security	or Exercise	(1.1011att 2 at), 1 car)	any	Code	of	(Month/Day/		Underl		Security	Secur
	(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	`	rear)	Securit		(Instr. 5)	Bene
	(111501. 5)	Derivative Security		(Mondi/Day/Tear)	(msu. o)	Securities	curities quired		(Instr. 3 and 4)	, ,	Own	
						Acquired					Follo	
						(A) or					Repo	
						Disposed						Trans
						of (D)						(Instr
						(Instr. 3,						(IIIsti
						4, and 5)						
						i, and 5)						
										Amount		
						Date	Expiration		or			
								Date	Title	Number		
										of		
					Code V	(A) (D)				Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Arch Venture Fund VII LP 8725 WEST HIGGINS ROAD, SUITE 290 CHICAGO, IL 60631		X					
ARCH Venture Partners VII, L.P. 8725 WEST HIGGINS ROAD, SUITE 290 CHICAGO, IL 60631		X					
ARCH Venture Partners VII, LLC 8725 WEST HIGGINS ROAD, SUITE 290 CHICAGO, IL 60631		X					
CRANDELL KEITH C/O ARCH VENTURE FUND VII 8725 WEST HIGGINS ROAD, SUITE 290 CHICAGO, IL 60631		X					
BYBEE CLINTON C/O ARCH VENTURE FUND VII 8725 WEST HIGGINS ROAD, SUITE 290 CHICAGO, IL 60631		X					

## **Signatures**

/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, as Managing Director of the general partner of the general partner of ARCH Venture Fund VII, L.P.					
**Signature of Reporting Person	Date				
/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, as Managing Director of the general partner ARCH Venture Partners VII, L.P.					
**Signature of Reporting Person	Date				
/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, as Managing Director of ARCH Venture Partners VII, LLC	06/20/2015				

Reporting Owners 2

#### Edgar Filing: Sage Therapeutics, Inc. - Form 4

\*\*Signature of Reporting Person

/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell 06/20/2015

Date

\*\*Signature of Reporting Person

Date

/s/ Mark McDonnell as Attorney-in-Fact for Clinton Bybee

06/20/2015

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Distribution of Common Stock held by a limited partnership to its partners for no consideration.
  - ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH Venture Fund VII, L.P. ("ARCH"), may be deemed to beneficially own certain of the shares held by ARCH. The GPLP disclaims beneficial ownership of all shares held by ARCH in which the GPLP does not have an actual pecuniary interest. ARCH Venture Partners VII, LLC (the "GPLLC"), as the sole general partner of the
- (2) GPLP, may be deemed to beneficially own certain of the shares held by ARCH. The GPLLC disclaims beneficial ownership of all shares held by ARCH in which it does not have an actual pecuniary interest. The managing directors of the GPLLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee (together, the "Managing Directors"), are deemed to have voting and dispositive power over the shares held by ARCH, and may be deemed to beneficially own certain of the shares held by ARCH.
- The Managing Directors disclaim beneficial ownership of all shares held by ARCH in which they do not have an actual pecuniary

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3